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Dependent Changes in Cellular Tyrosine Phosphorylation
A. D. CATLING,t V. J. FINCHAM, M. C. FRAME, B. HAEFNER, AND J. A. WYKE*
CRC Beatson Laboratories, Beatson Institute for Cancer Research, Bearsden,
Glasgow G61 JBD, United Kingdom
Received 2 February 1994/Accepted 17 March 1994
We have analyzed two functionally significant amino acid alterations encoded by the temperature-sensitive
(ts) v-src mutant of Rous sarcoma virus, LA32. The G-to-V change at residue 300 in the catalytic domain
nonconditionally impairs morphological transformation, in vitro kinase activity, in vivo tyrosine phosphory-
lation, and the cytoskeletal association of v-Src while rendering anchorage- and serum-independent growth ts.
The R-to-P mutation in the SH3 domain subtly enhances morphological transformation but has no phenotype
if the catalytic domain is inactivated. In the presence of the G-300-to-V mutation, this SH3 domain lesion does
not affect v-Src in vitro kinase activity and cytoskeletal association, but it nonconditionally enhances cellular
tyrosine phosphorylation and restores morphological transformation at the permissive temperature only. This
ability to induce a ts transformed morphology, in concert with nonconditional elevations of cellular
phosphotyrosine, suggest that a subset of v-Src targets that are crucial to transformation may be affected in
ts fashion by the SH3 mutation. Consistent with this, we find that the R-107-to-P mutation confers ts activity
and tyrosine phosphorylation on the SH3-binding enzyme phosphatidylinositol 3'-kinase. Thus, both the SH3
and catalytic domain mutations in LA32 have some ts attributes and they cooperate in determining the
mutant's behavior. The ts SH3 mutation is unique and offers the potential for deeper understanding of the
function of this domain.
The v-src oncogene product, pp6ovsrc (v-Src), is a non-
receptor protein tyrosine kinase that comprises several do-
mains, including a catalytic region (amino acids 260 to 514)
and Src homology (SH) domains, SH2 (amino acids 140 to
250) and SH3 (amino acids 85 to 139). There is abundant
evidence that v-Src exerts all or most of its neoplastic effects on
cells through its kinase domain activity, but it is also apparent
that the consequences of this activity are modulated, and
presumably given specificity, by other domains, including SH2
and SH3. The SH2 and SH3 domains (reviewed in references
16, 21, and 22) bind phosphotyrosine-containing peptides and
proline-rich peptides, respectively, and are found in many
proteins, notably the small adaptor proteins such as Crk. Their
domain structures have recently been determined (36, 41).
These findings encourage the view that both domains are
self-contained modules that determine the interactions of
proteins that contain them but that do not affect the inherent
structures or functions of contiguous protein domains. How-
ever, both SH2 and SH3 domains appear to participate in
intramolecular interactions that maintain c-Src kinase in an
inactive state (20, 30). There are thus unsubstantiated possi-
bilities in v-Src for these domains to interact with one another
or with the catalytic or other regions of the protein (1, 34).
This conjecture rekindled our interest in a temperature-
sensitive (ts) v-src mutant of Rous sarcoma virus (RSV), LA32,
which encodes alterations in both the SH3 domain (R at amino
acid 107 to P [R107P]) and the kinase domain (G at position
300 to V [G300V] and R at 419 to Q [R419Q]) (40). In chicken
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embryo fibroblasts (CEF) at the permissive temperature
(35°C), this mutant protein induced anchorage-independent
growth in agar, and the morphology of transformed cells on a
substrate was refractile, but fusiform rather than round. At the
restrictive temperature (41°C), agar growth was much reduced
and the cellular morphology resembled that of uninfected CEF
(28). However, although both the in vitro tyrosine kinase
activity and the plasma membrane association of this protein
were reduced, neither was markedly ts, nor was there any
discernible defect in the biogenesis or amino-terminal myristy-
lation of LA32 v-Src at either temperature (29). Moreover, the
candidate v-Src substrates calpactin and vinculin were phos-
phorylated at both 35 and 41°C, and there was no temperature
sensitivity in total cellular phosphotyrosine levels (14, 28).
These initial findings indicated that neither the catalytic
activity nor the gross localization of LA32 v-Src differed
markedly between permissive and restrictive conditions. We
therefore postulated that the ts phenotype resulted, at least in
part, from subtle changes in the protein's cellular interactions,
possibly mediated by the SH3 domain mutation. This report
examines that hypothesis by analyzing the individual and
combined effects of the SH3 and kinase domain mutations on
the biochemical attributes and biological effects of v-Src. Many
analyses were performed in Rat-1 cells as well as CEF, and
since where this was done the results were similar in both hosts,
we present examples of data from both species. These data
showed that the G300V mutation constitutively impaired the
function of the kinase domain and consequent cellular trans-
formation but transformation was restored by the R107P
lesion, and under these conditions, both mutations could
contribute to the temperature sensitivity of the phenotype. In
addition, although cellular tyrosine phosphorylation was ele-
vated at the restrictive temperature, at least one candidate
target of v-Src was shown to be ts in function and tyrosine
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FIG. 1. Diagrammatic domain structure of RSV wild-type (PP)
Prague A (PR-A) strain v-Src and the position of mutations in ts
mutant LA32 (MM) and chimeric MP and PM proteins. R/Q indicates
that the presence of either arginine or glutamine at this site is
immaterial to the protein's behavior.
phosphorylation in a manner dependent on the SH3 domain
mutation.
MATERIALS AND METHODS
Cells, plasmids, and viruses. CEF were prepared from
10-day-old White Leghorn embryos (Wickham Laboratories,
Hampshire, England). Culture, including focus and soft agar
growth assays, employed standard techniques of this laboratory
(31, 39).
The v-src genes of the wild-type Prague A strain of RSV and
its ts mutants LA29 and LA32 had previously been cloned in
this laboratory (7, 27, 37). For introduction of these genes into
mass cultures of CEF, full-length viruses were constructed by
using a pRAV vector (33) as previously described (37), and 106
cells were transfected with 1 jig of plasmid DNA by using
transfection reagent (Boehringer Mannheim, Lewes, En-
gland). To obtain Rat-1 cell lines, the v-src genes were cloned
into the selectable mammalian vector fpGV-1 (24) (kindly
provided by G. S. Martin), and 106 cells were transfected with
5 jig of plasmid DNA and then subjected to selection with
G418 (Gibco, Paisley, Scotland) and cloning by micromanipu-
lation.
Chimeras between wild-type and LA32 v-src, as depicted in
Fig. 1, were made by subcloning appropriate combinations cut
at the v-src BglII site (nucleotide 7736). Mutant v-src with an
inactive kinase was constructed by replacing the K295 codon
with an R codon, using PCR techniques (32). The identity and
integrity of all clones were confirmed by sequencing.
Cell fractionation. The separation of detergent-soluble and
cytoskeletal cell fractions was done as described previously
(37). Briefly, cells at the appropriate temperature were la-
belled for 3 h with [35S]methionine (Amersham International,
Amersham, England) at 100 ,uCi/ml and then incubated thrice
with MCSK buffer (20 mM N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid [HEPES; pH 6.8], 3 mM MgCl2, 50 mM
NaCl, 0.3 M sucrose, 0.5% Nonidet P-40 [NP-40], 1 mM
CaCl2) on ice to yield the detergent-soluble fraction. The
residual fraction was solubilized in NP-40 buffer (1% NP-40,
150 mM NaCl, 20 mM Tris-HCI [pH 6.8], 20 mM sodium
pyrophosphate, 10 mM sodium orthovanadate, 2 mM phenyl-
methylsulfonyl fluoride, 1 jig of aprotinin per ml). Src was
immunoprecipitated with monoclonal antibody JB327 (Onco-
gene Science, Cambridge, England), resolved on sodium do-
decyl sulfate (SDS)-10% polyacrylamide gels, and visualized
by impregnation with Amplify (Amersham) followed by drying
and autoradiography.
In vitro kinase assays. Cells were lysed in NP-40 buffer and
clarified, and v-Src was immunoprecipitated with antibody
JB327. The washed precipitate was incubated for 5 min at 30°C
with 5 ,uCi of [_y-32P]ATP (3,000 Ci/mmol; Amersham) and 8
,ug of rabbit muscle enolase (Sigma, Poole, England) in kinase
buffer [100 mM piperazine-N,N'-bis(2-ethanesulfonic acid)
(PIPES; pH 6.8), 2 mM MnCl2, 10 ,uM sodium orthovanadate).
The reaction was stopped with NP-40 wash buffer (10 mM
Tris-HCl [pH 8], 400 mM NaCl, 1 mM EDTA, 1% NP-40,
0.25% sodium deoxycholate), the precipitates were washed
thrice, and substrates were resolved on SDS-10% polyacryl-
amide gels.
Phosphoamino acid analysis. The analysis was done by the
method of Cooper et al. (3). Briefly, cells in phosphate-free
medium, supplemented with 5% dialyzed newborn calf serum,
were incubated for 18 to 20 h in carrier-free 32p; (1 mCi/ml;
Amersham), washed, and lysed on ice in modified radioimmu-
noprecipitation assay (RIPA) buffer (10 mM Tris-HCl [pH 7],
150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1%
SDS, 2 mM EDTA, 10 mM sodium pyrophosphate, 10 mM
P-glycerophosphate, 10 jiM sodium orthovanadate, 2 mM
phenylmethylsulfonyl fluoride, 1 jig of aprotinin per ml). After
clarification, proteins were extracted and hydrolyzed, and
hydrolysates, together with unlabelled phosphodmino acid
standards, were spotted on a cellulose thin-layer plate (20 by 20
cm; Kodak). Following electrophoresis in two dimensions at
pH 1.9 and 3.5, respectively, standards were visualized with
ninhydrin to identify areas for scraping and counting.
Protein blotting. Cells were lysed in modified RIPA buffer
(as described above but with phosphate-buffered saline in
place of Tris-HCl), and protein concentrations were deter-
mined by the Micro BCA method (Pierce, Chester, England).
For direct analysis of v-Src and phosphotyrosine, 25 or 50 jig of
protein was resolved on SDS-10% polyacrylamide gels, trans-
ferred to nitrocellulose, and probed with either v-Src mono-
clonal antibody EC10 (UBI, TCS Biologicals, Botolph Clay-
don, England) or antiphosphotyrosine monoclonal antibody
Py2O (UBI). To examine phosphotyrosine levels in the p85
subunit of phosphatidylinositol (PI) 3'-kinase, 500 ,ug of RIPA
lysates was first immunoprecipitated with polyclonal p85 anti-
body (UBI). Detection was by enhanced chemiluminescence
(Amersham) as instructed by the manufacturer.
PI 3'-kinase assay. Cells were grown to 90% confluence on
rat tail collagen 1 (Stratech, Luton, England) at the appropri-
ate temperature, washed, and rapidly lysed in PLC lysis buffer
(15). Clarified lysates were incubated overnight with protein
A-Sepharose beads (Sigma) coated with v-Src monoclonal
antibody EC10 (UBI), control normal mouse immunoglobulin
G (ICN, High Wycombe, England), or polyclonal p85 antibody
(UBI). Washed immunoprecipitates were then incubated in
assay buffer (50 mM HEPES, 10 mM NaCl, 1 mM EDTA [pH
7.4]) with a 3:1 mixture of PI and phosphatidylserine (0.02
mg/ml) and with 50 ,uM ATP, 50 jiCi of [y-32P]ATP, and 10
mM MgCl2 as substrates for 30 min at 30°C. Reaction products
were extracted and separated by thin-layer chromatography.
After autoradiography, the PI 3-phosphate band was scraped
off the plate and counted.
RESULTS
Mutations in v-src. The three mutations of LA32 were
examined singly and in all combinations of doubles in a variety
of biological and biochemical tests. The mutant proteins were
designated by a two-letter code which identified a mutant (M)
or wild-type (P) amino acid at position 107 (first letter) or 300
(second letter) (Fig. 1). The mutation at position 419 has no
apparent biological significance, since in all tests, the amino
VOL. 68, 1994
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FIG. 2. Morphologies at permissive (35°C) and restrictive (41°C) temperatures of mass cultures of CEF after transfection with the pRAV vector
or constructs bearing chimeric v-Src proteins as identified in Fig. 1. Cultures in panels F and L were infected for several days longer and maintained
under an agar overlay.
acid at this position was immaterial to the result, and its
identity is not included in the mutant designation.
Biological effects of v-src mutations. As previously shown
(28), MM v-Src proteins induced a morphology that was
transformed but fusiform at 35°C and similar to that of
uninfected chick cells at 41°C (Fig. 2A, C, G, and I). PP
proteins induced transformation at both temperatures (Fig. 2E
and K) and chimeric MP proteins were also markedly trans-
forming at both 35 and 41°C (Fig. 2B and H). Indeed, the latter
induced a more rounded cellular phenotype in cultures, which
could be maintained in an attached state only in collagen-
coated dishes. In contrast, PM v-Src induced very little mor-
phological change at either temperature (compare Fig. 2D and
J with Fig. 2A and G, respectively). However, when cultured
under focus assay conditions (a week or more under agar), PM
chimeras elicited macroscopically visible thickenings of the cell
layer at 35 but not 41°C. These foci contained aligned and
somewhat refractile cells, contrasting with the indistinct cell
boundaries in cultures kept at 41°C (Fig. 2F and L).
Anchorage-independent growth in agar partly paralleled the
morphological changes, with PP and MP v-Src inducing large
colonies at both temperatures, although those induced by MP
were more compact at the restrictive temperature (Fig. 3C to
F). MM chimeras were ts for growth (Fig. 3A and B), while PM
proteins, although inducing only slight morphological changes,
were clearly also capable of inducing growth in agar which was
ts, but less obviously so than that induced by MM (Fig. 3G and
H). In common with other ts transformation mutants of v-Src,
cells containing MM and PM v-Src were arrested in the Go
phase of the cell cycle by serum deprivation at the restrictive
temperature (reference 38 and references therein). When
shifted to permissive conditions, the MM chimera induced cell
cycle progression with kinetics similar to those produced by
addition of 5% serum. Cells containing the PM chimera, but
not control cells containing vector alone, also progressed
significantly through the cell cycle at 35°C, although the effect
was less than for MM (data not shown).
These results show that the LA32 G300V mutation impairs
morphological transformation at both permissive and restric-
tive temperatures and renders the virus partially ts for growth-
promoting activity, as judged by focus formation and anchor-
age- and serum-independent growth. The R107P mutation has
a compensatory effect, restoring morphological transformation
at the permissive temperature but not affecting, and indeed
possibly augmenting, the temperature sensitivity mediated by
the mutation at position 300.
Localization of v-Src. When the subcellular distribution of
LA32 (i.e., MM) v-Src protein was determined by fractionation
of Dounce-homogenized CEF, the proportion in the crude
membrane pellet was reduced by about 5% at 35°C and by
about 40% at 41°C compared with the wild-type (PP) protein
(29). The partitioning of chimeric proteins between the soluble
and cytoskeletal cellular compartments was therefore ana-
lyzed. We found that the reduced cytoskeletal association of
MM proteins was shared by PM chimeras, while both MP and
PP proteins were mainly cytoskeletal under the conditions of
J. VIROL.
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FIG. 3. Anchorage-independent growth of Rat-1 clones expressing
chimeric v-Src molecules at permissive (35°C) and restrictive (39°C)
temperatures. Colonies formed in soft agar (39) were photographed 10
to 14 days after seeding.
this assay (Fig. 4). There were no temperature-dependent
variations in the relative distribution of any chimeric proteins,
although the overall incorporation of label during the 3-h
incubation tended to be higher at 41'C. Table 1 shows the
mean cytoskeletal distribution of pp600rc, determined by den-
sitometric scanning of three separate experiments. These
figures overestimate the actual cytoskeletal levels of v-Src in all
cases, since pp6Ocsrc formed a low background, which was
mainly in the cytoskeletal compartment (Fig. 4). The cytoskel-
etal levels of MM protein were therefore lower than antici-
pated from the distribution determined by Dounce homogeni-
zation. It is thus possible that MM protein is concentrated at
the cell periphery, as also suggested by immunofluorescence
(29), but this association is more labile and the protein is more
readily solubilized by MCSK buffer than is wild-type v-Src, a
feature conferred by the G300V mutation.
1 2 3 4 5 6 7 8
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FIG. 4. Subcellular localization of v-Src. CEF labelled for 3 h with
[35S]methionine were separated into detergent-soluble (S; odd-num-
bered lanes) and cytoskeletal (C; even-numbered lanes) fractions,
from which Src was immunoprecipitated. Lanes 9 to 12 are fractions
from cells bearing the pRAV vector alone; the others express chimeras
as indicated.
Biochemical effects of v-src mutations. In vitro kinase assays
were performed with v-Src immunoprecipitated from CEF
with monoclonal antibody 327, using acid-denatured enolase as
the substrate. The results with similar quantities of proteins
(Fig. 5A) showed considerable activity by PP and MP v-Src
proteins and little activity above background on the part of
MM and PM chimeras. Other sera, including polyclonal v-Src
antisera from tumor-bearing rabbits, gave the same result,
showing that it was not an artifact of the recognition of an SH3
domain epitope by monoclonal antibody 327 (2). Comparable
results were obtained with v-Src proteins from transfected
Rat-1 cells, and none of these proteins showed ts behavior in
this assay (reference 2 and data not shown).
In spite of its constitutively reduced in vitro kinase activity,
we have previously shown that MM v-Src protein can elevate
intracellular phosphotyrosine levels in both morphologically
transformed (35'C) and normal (41'C) CEF (28). In Rat-1
cells (Table 2), phosphotyrosine levels induced by LA32 v-Src
were also not ts, in contrast to the LA29 mutant protein, but
they were two- to threefold lower than the relative levels
induced by wild-type v-Src. This reflects exactly the behavior of
these proteins in CEF, although Rat-1 cells had relative levels
TABLE 1. Cytoskeletal association of chimeric v-Src proteins
% pp6O"' in cytoskeletal
Chimera fraction'
35°C 410C
None (vector alone) 77b 82b
MM 33 25
PP 87 83
MP 83 90
PM 26 29
a Determined by densitometric scanning and expressed as a percentage of total
soluble plus cytoskeletal fractions. Values are means of three independent
expenments of the type shown in Fig. 4.bpp60(csc alone.
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FIG. 5. (A) In vitro phosphotransferase activities of Src proteins from CEF at 35°C, using rabbit muscle enolase as the substrate. Lane 1, CEF
containing pRAV vector alone. Other lanes display comparable amounts of chimeric v-Src as indicated. (B and C) Duplicate protein blots from
CEF probed with either antiphosphotyrosine monoclonal antibody Py2O (B) or anti-v-Src monoclonal antibody EC10 (C). Lanes: 1, cells containing
pRAV vector alone; 2 to 9, cells expressing chimeric v-Src as indicated and grown at either the permissive (even-numbered lanes) or restrictive
(odd-numbered lanes) temperature. Positions of molecular weight markers (in kilodaltons) are shown to the right of panel B.
of phosphotyrosine that were universally about 10-fold lower
than in counterpart CEF (28). These data present a paradox
which may be explicable if the low MM kinase activity is an in
vitro artifact or is nonetheless sufficient to increase the intra-
cellular phosphotyrosine level. It is also possible that the
elevation of the cellular phosphotyrosine level is due entirely
or in part to the SH3 domain mutation, the v-Crk oncoprotein
providing a precedent for a protein that increases tyrosine
phosphorylation indirectly by way of its SH2 and SH3 domains
(17).
To investigate these possibilities, we examined the ability of
v-Src chimeras to elevate tyrosine phosphorylation in total
cellular proteins (Fig. 5B). All of the chimeras increased
phosphotyrosine levels, but to markedly different extents; since
the levels of v-Src in these cells were comparable (Fig. 5C), the
abilities to phosphorylate tyrosine were in the order PP > MP
> MM > PM. This ranking accorded with the behavior of PP
and MM proteins in Table 2 and may reflect in part the greater
ability of PP and MP proteins to locate at the cytoskeleton
(Fig. 4), but it also suggests that the low in vitro kinase activity
associated with the G300V mutation (Fig. 5A) is not simply
artifactual. The R107P lesion enhances tyrosine phosphoryla-
tion only in the context of a mutant residue 300 (chimera MM);
to check whether this represents an independent activity of the
v-Src SH3 domain, the MM kinase was fully inactivated by
mutating the lysine at position 295 to arginine (references 11
and 26 and data not shown). This triple mutant was unable to
induce morphological transformation or anchorage-indepen-
TABLE 2. Relative abundance of phosphotyrosine in Rat-1 clones
expressing v-Src
Relative abundance of
Clone phosphotyrosinea
350C 390C
Rat-1 fPrA (PP) 0.12 0.08
Rat-1 f29 (LA29) 0.036 0.019
Rat-1 f32 (MM) 0.037 0.048
a Phosphoamino acids were scraped from cellulose plates, together with
appropriate background areas. Phosphotyrosine levels are expressed as percent-
ages of the total radioactivity in phosphoserine, phosphothreonine, and phos-
photyrosine after subtracting background counts. Very similar results were
obtained in three independent experiments. Levels in Rat-1 cells were not
detectably above the background levels.
dent growth, and more significantly, it also failed to elevate
tyrosine phosphorylation of cellular proteins (data not shown).
Thus, although the R107P mutation compensates for the
G300V lesion, any effect of the SH3 domain mutation depends
on residual kinase domain activity. The SH3 domain of LA32
does not enhance tyrosine phosphorylation independently of
the catalytic domain.
A ts target for LA32. The data presented above show that the
G300V mutation in chimera PM is responsible for a constitu-
tively low in vitro kinase activity (Fig. 5A) and poor cytoskel-
etal localization of v-Src (Fig. 4; Table 1). These effects are
associated with reduced cellular tyrosine phosphorylation (Fig.
SB) which is sufficient to induce altered cell growth but not
marked morphological changes (Fig. 2 and 3). The additional
presence of the R107P mutation (chimera MM) does not
significantly affect the subcellular localization or in vitro kinase
activity of PM v-Src, but it enhances cellular tyrosine phos-
phorylation and restores morphological transformation. This
transforming capacity is, however, ts (Fig. 1), whereas cellular
tyrosine phosphorylation is not grossly temperature dependent
(Table 2; Fig. SB), in keeping with earlier phosphoamino acid
analyses of LA32 v-Src (28). We have previously argued that
LA32 is a minimal-deviation mutant, which differs only slightly
in tyrosine phosphorylation at permissive and restrictive tem-
peratures and thus has the potential to discriminate essential
v-Src targets from adventitious substrates and those that may
be necessary but are not sufficient for transformation (40). The
present investigation substantiates that view and further sug-
gests that the proposed subset of crucial targets, whose phos-
phorylation by LA32 v-Src is ts, includes those whose interac-
tions with v-Src are enhanced by the SH3 domain mutation,
thus conferring a transformed cell morphology in the presence
of the G300V mutation. We therefore examined the effect of
chimeric v-Src proteins on the function and tyrosine phosphor-
ylation of a candidate target that binds to the v-Src SH3
domain, PI 3'-kinase (15).
The v-Src-associated activity of PI 3'-kinase was enhanced in
chick cells expressing all of the chimeric v-Src proteins (Fig.
6A), but the enhancement by PM was relatively slight, and in
common with the effect of PP, it was not temperature depen-
dent. In contrast, expression of both MP and MM proteins was
associated with a reduction of more than twofold in PI
3'-kinase activity at the restrictive temperature, although MP
induced overall higher levels than MM. Thus, the activity of
J. VIROL.
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FIG. 6. (A) CEF PI 3'-kinase activity associated with indicated
chimeric v-Src proteins at permissive and restrictive temperatures.
Assays were performed as described in Materials and Methods,
reaction products were separated by thin-layer chromatography, and
the PI 3-phosphate band was scraped off the plate and counted. An
example of one assay is shown, but comparable results were obtained
in three independent determinations. (B) Blot of immunoprecipitated
p85 subunit of PI 3'-kinase probed with antiphosphotyrosine mono-
clonal antibody Py2O. Lanes: 1, CEF lysate immunoprecipitated with
preimmune serum; 2 and 3, CEF containing pRAV vector alone; 4 to
7, CEF expressing the indicated v-Src chimeras. Lanes 3, 5, and 7 are
samples from cells shifted to the permissive temperature from 41°C 16
h earlier. Positions of molecular weight markers (closed arrowheads)
are shown (in kilodaltons) on the right, as are the positions of the two
p85 species precipitated by the antiserum (open arrowheads).
this SH3-binding protein is enhanced, but in ts fashion, by the
R107P mutation, whereas activation is constitutively dimin-
ished by the G300V lesion. The role of the R107P mutation
was further demonstrated by the tyrosine phosphorylation of
the p85 subunit of PI 3'-kinase (Fig. 6B). PM v-Src induced
significant tyrosine phosphorylation of p85 at both restrictive
and permissive temperatures, whereas tyrosine phosphoryla-
tion by the MM chimera was markedly ts.
DISCUSSION
Random mutagenesis of v-src, followed by selection of the
desired phenotype, may give serendipitous information on the
interplay of mutations that is not readily obtained by site-
directed approaches. This is the case with LA32, in which the
R107P and G300V mutations both contribute to the altered
phenotype, although the effect of the SH3 lesion may have
escaped detection in the absence of the kinase domain muta-
tion.
The catalytic domain mutation. At both permissive and
restrictive temperatures, the catalytic domain mutation drasti-
cally impairs in vitro tyrosine kinase activity and its conse-
quences and reduces the ability of v-Src to associate with the
cytoskeleton. DeClue and Martin (4) found that v-Src linker
insertion mutations at amino acids 299 and 300 were, like
LA32, ts for transformation with a lowered, but not ts, in vitro
kinase activity. They also found that mutant v-Src complex
formation during biogenesis with the pp9O and pp5O proteins
was higher at 41°C, but this latter phenomenon cannot explain
the reduced MM cytoskeletal association, for LA32 v-Src
complex formation is the same as for wild-type protein (29)
and cytoskeletal association is not ts (Fig. 4). We have not,
however, tested complex formation with the PM chimera, and
it remains possible that the SH3 domain mutation in LA32
v-Src compensates for faulty complex formation mediated by
the G300V mutation. With this caveat, we favor the probability
that the G300V mutation increases the functional lability of
v-Src, as revealed in both in vitro and in vivo investigations
(Fig. 4 and 5). However, the mutant kinase domain retains
some function, even at the restrictive temperature (Fig. 5B),
and it can interact with the R107P mutation to elevate cell
tyrosine phosphorylation, whereas the kinase inactive K295R
mutation cannot.
The SH3 domain mutation. The SH3 domain contributes to
the tight regulation of c-Src protein activity (20, 30), and
mutations to c-Src SH3 tend to abrogate this regulation and
enhance c-Src activity (6, 13, 23, 25). SH3 mutations in v-Src or
activated c-Src proteins have shown either little effect or
variously impaired cell transformation, agar growth, or kinase
activity (8-10, 12, 35), although such studies are probably
inherently biased toward the detection of deleterious effects. In
the PA101 mutant of RSV, SH3 domain substitutions at
residues 85 and 105 confer a fusiform morphology (18), and
complex second-site mutations to residues 87 to 92, including
a deletion of three amino acids, restore the round phenotype
of the parental Bryan strain protein (5). To our knowledge,
however, the LA32 R107P mutation is unique in enhancing the
function of wild-type v-Src, for although its effect is striking in
the context of the G300V mutation, which cripples catalytic
domain function, it persists in MP chimeras, which are even
more markedly transforming than the wild-type PP protein
(Fig. 2).
Domain interactions. There is clearly an interplay between
SH3 and catalytic domain mutations in LA32 v-Src which
influences the integrated functions of the protein. The R107P
mutation has no effect if the kinase is completely inactive, so it
is not functioning as an adaptor module analogous to v-Crk. It
may have an altered protein binding affinity or may bind a
different spectrum of proteins which are thus exposed to, and
enhance the effects of, the kinase domain activity, particularly
in its enfeebled mutant form. Nuclear magnetic resonance
studies have identified SH3 amino acids whose chemical shifts
were changed by binding of candidate ligands (41), and
substitutions of some of these putative ligand binding site
residues alter SH3 function to variable extents (5, 6, 8, 9, 12,
23, 35). Residue 107 is, however, not implicated in ligand
binding, in common with certain other residues whose substi-
tutions nonetheless have marked biological consequences (8-
10, 35). The E106K substitution and deletion of residue 105
studied by Wages et al. (35) both impair SH3 function in
concert with a reduction in the v-Src-associated activity of PI
3'-kinase, a protein known to bind SH3 (15). Although this
finding suggests that these mutations affect ligand binding, it
does not prove it, and the R107P substituted SH3 domain
clearly binds active PI 3'-kinase, albeit in a ts fashion (Fig. 6
and reference 7a). Moreover, modelling studies based on the
SH3 structure of Yu et al. (41) indicate that the R107P change
has no effect on the ligand binding site (19), but its proximity
to the amino and carboxy extremities of SH3 may affect the
linkage of SH3 to the rest of the v-Src protein. This prediction,
which is testable by structural studies, raises the further
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possibility that the function of the SH3 module is affected by its
relationship with other v-Src domains. There could be an
unchanged spectrum of proteins binding to the mutant SH3
region, but their disposition to the SH2 and catalytic domains
could be altered, with consequent effects on their tyrosine
phosphorylation (as in Fig. 6B) or the binding of v-Src to
phosphotyrosine residues in the same or other proteins.
Temperature sensitivity of LA32. LA32 v-Src confers a ts
transformed phenotype but elevates cellular phosphotyrosine
at both permissive and restrictive temperatures, suggesting
that LA32 temperature sensitivity is due to the conditional
activation and/or tyrosine phosphorylation of a small number
of crucial target molecules. These include PI 3'-kinase (Fig. 6)
but not calpactin or vinculin, which are both phosphorylated to
the same levels, independently of temperature (14, 28). Al-
though we cannot conclude that the latter two molecules are
irrelevant to transformation, since their phosphorylation may
be a necessary but insufficient prerequisite, the data do imply
an important role for PI 3'-kinase in transformation. The SH3
mutant studies of Wages et al. (35) correlate decreased
association between PI 3'-kinase and v-Src with impaired
morphological transformation, suggesting that PI 3'-kinase is
important in regulating cell morphology. The poor activation
of the enzyme at 41°C in fully transformed cells expressing MP
v-Src (Fig. 6A) seems at odds with this suggestion, but the
efficient membrane localization of MP v-Src (Fig. 4) may result
in enough PI 3'-kinase activity at the appropriate cellular
location to ensure transformation. We are testing this possi-
bility.
Another question for further study is why LA32 v-Src effects
on PI 3'-kinase are ts when there is no evidence for tempera-
ture sensitivity of either kinase activity in vitro or of tyrosine
phosphorylation on other proteins (14, 28). It is possible that
the ts effects of the LA32 mutations are apparent only when
protein is bound to the SH3 or SH2 domain. Such v-Src
molecules may themselves be a subset of proteins whose kinase
activity depends largely on appropriate cellular contexts, since
MM kinase functions well at both temperatures in vivo (Fig.
SB) but has poor activity in in vitro assays with total cell protein
(Fig. SA). These considerations further imply that changes to
SH3 can alter the behavior of other v-Src domains, and we plan
to exploit the temperature sensitivity of LA32 and its chimeras
in investigating these interactions.
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